ONCOLOGY Vol 14 No 3
-
-
Commentary
-
Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
-
FHIT Gene, Smoking, and Cervical Cancer
-
Commentary
-
Photodynamic Therapy in Lung Cancer
-
Commentary
-
Commentary
-
Commentary
-
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
-
Commentary
-
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
-
IOM Medical Error Estimates Questioned, But Legislation Considered
-
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
-
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
-
High-Dose Therapy for Follicular Lymphoma
-
Commentary
-
High-Dose Therapy for Follicular Lymphoma
-
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
-
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
-
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
-
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
-
Regional Strategies for Managing Hepatocellular Carcinoma
-
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
-
Photodynamic Therapy in Lung Cancer
-
Commentary
-
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
-
Commentary
-
New Antibiotic Effective in Treating Gram-Positive Bacteremia
-
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
-
Long-Term Follow-Up Data on M-Vax Cancer Vaccine
-
Substantial Activity of Thalidomide in Multiple Myeloma, Study
-
Commentary
-
Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients With Mantle Cell Lymphoma
-
Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
-
Management of Venous Thromboembolism in Cancer Patients
-
Commentary
-
Commentary
-
In Vivo Purging With Rituximab During Stem Cell Transplantation for Indolent Lymphoma
-
How Doctors Break Bad News
-
High-Dose Therapy for Follicular Lymphoma
-
Excellent Tolerance of Rituxan When Given After Mitoxantrone-Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin’s Lymphoma
-
Epratuzumab, a New Anti-CD22, Humanized, Monoclonal Antibody for the Therapy of Non-Hodgkin’s Lymphoma: Phase I/II Trial Results
-
Commentary
-
Book Review:Childhood Leukemias
-
Multicenter Study of Campath-1H in Patients With Chronic Lymphocytic Leukemia Refractory to Fludarabine
-
In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma
-
Bexxar (Tositumomab, Iodine-131 Tositumomab) Can Be Safely Administered in Relapsed Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma Patients After Prior Treatment With Rituximab: Initial Experience From the Expanded Access Study
-
Phase I/II Study of Thrice-Weekly Rituximab in ChronicLymphocytic Leukemia/Small Lymphocytic Lymphoma: A Feasible and Active Regimen
-
Management of Venous Thromboembolism in Cancer Patients
-
Meta-analysis: Methods, Strengths, and Weaknesses
-
Regional Strategies for Managing Hepatocellular Carcinoma
-
Phase II Study of Rituximab in Previously Treated Patients With Multiple Myeloma: Progress Report
-
Commentary
-
Campath-1H Therapy in 29 Patients With Refractory CLL: ‘True’ Complete Remission is an Attainable Goal
-
Commentary
-
Efficacy and Safety of CMA-676 in Patients With Acute Myelogenous Leukemia in First Relapse
-
Rituximab in the Treatment of Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma
-
Rituximab/CHOP Chemoimmunotherapy in Patients With Low-Grade Lymphoma: Progression-Free Survival After 3 Years’ Follow-Up
-
Pilot Study of Rituximab in Refractory or Relapsed Hairy Cell Leukemia
-
Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience
-
Management of Venous Thromboembolism in Cancer Patients
-
Commentary
-
Regional Strategies for Managing Hepatocellular Carcinoma
-
Commentary
-
NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned
-
Safety of Fludarabine, Mitoxantrone, and Dexamethasone Plus Rituximab in the Treatment of Stage IV Indolent Lymphoma
-
Toxicity and Efficacy of the Anti-CD20 Antibody Rituximab (Rituxan) in Patients With B-Cell Chronic Lymphocytic Leukemia: A Phase I/II Study
-
Rituximab Retreatment Can Produce Prolonged Failure-Free Survival for Relapsed Indolent B-cell Lymphoma
-
Prostate Surgeries: Average Charges Throughout the United States, 1997
-
Fludarabine Monophosphate Followed by Iodine-131 Tositumomab Fludarabine Monophosphate Followed by Iodine-131 Tositumomab (NHL)
-
Zevalin (IDEC-Y2B8) Radioimmunotherapy of Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results
-
Photodynamic Therapy in Lung Cancer
-
Chimeric Anti CD20 Monoclonal Antibody (Rituximab) in B-Post-transplant Lymphoproliferative Disorders: A Retrospective Analysis of 32 Patients
-
Treatment of Patients With Mantle Cell and Aggressive B-Cell Non-Hodgkin’s Lymphoma Using the Monoclonal Anti-CD20 Antibody Rituximab: Evaluation of Safety and Response
-
Meta-analysis: Methods, Strengths, and Weaknesses
-
Interferon-Gamma Induces CD20 Expression on Multiple Myeloma Cells via Induction of Pu.1 and Augments Rituximab Binding to Myeloma Cells
-
Biological and Clinical Evaluation of Rituximab in the Management of Newly Diagnosed Multiple Myeloma Patients
-
Rituximab as First-Line Treatment of Patients With Follicular
|
|
